Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of CLARA versus High-Dose Cytarabine Consolidation in Intermediate/Unfavorable-Risk AML
2008-000668-18Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of clofarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoints: Disease-free survival at 2 years and Safety profile. Started Mar 2009; status: completed.
02
Drugs
clofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2008-000668-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000668-18.